lenalidomide,mor00208,tafasitamab
incyte,morphosys
['l-mind', 'lymphoma', 'dlbcl', 'morphosys']
at #ash22, we re presenting an additional analysis of long-term data from the phase 2 l-mind study that suggests durable responses in adults with relapsed or refractory diffuse large b-cell lymphoma (#dlbcl). 
Global commercial-stage biopharmaceutical company driven by our mission: More life for people with cancer.